Luo X Q, Gong Y L, Zhang C, Liu M X, Shi Y L, Peng Y Z, Li N
State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Burn Research, the First Affiliated Hospital of Army Medical University (the Third Military Medical University), Chongqing 400038, China.
Zhonghua Shao Shang Za Zhi. 2020 Jan 20;36(1):24-31. doi: 10.3760/cma.j.issn.1009-2587.2020.01.005.
To analyze the distribution and drug resistance of pathogens isolated from patients with catheter-related bloodstream infection (CRBSI) in burn intensive care unit (BICU). From January 2011 to December 2018, among 2 264 patients who were peripherally inserted central venous catheter at the BICU of the First Affiliated Hospital of Army Medical University (the third Military Medical University), hereinafter referred to as the author's unit, 159 patients were diagnosed CRBSI, including 131 males and 28 females, aged 43 (1, 79) years. The pathogens primarily isolated from peripheral venous blood and central venous catheter blood/anterior central venous catheter specimen of patients with CRBSI were retrospectively analyzed. API bacteria identification kits and automatic microorganism identification instrument were used to identify pathogens. Broth micro-dilution method or Kirby-Bauer paper disk diffusion method was used to detect the drug resistance of the pathogens to 5 antifungal drugs including fluconazole and itraconazole, etc., and 37 antibacterial drugs including tigecycline and imipenem, etc. Modified Hodge test was used to further identify imipenem- and meropenem-resistant . D test was used to detect erythromycin-induced clindamycin resistant . The WHONET 5.6 software was applied to analyze the annual incidence of CRBSI, mortality of patients with CRBSI, incidence of CRBSI cases, distribution of infection site, and duration of catheterization, detection of Gram-negative and Gram-positive bacteria, fungi, methicillin-resistant (MRSA), and methicillin-sensitive (MSSA), and drug resistance of fungi and major Gram-negative and Gram-positive bacteria to the commonly used antibiotics in clinic. (1) The incidence of CRBSI was 7.0% (159/2 264) during the eight years, which was slightly higher in 2014 and 2017 with 13.6% (30/221) and 11.1% (24/217) respectively. The mortality rate of patients with CRBSI was 7.5% (12/159). (2) The incidence of CRBSI cases was 14.9% (338/2 264); the main infection site was femoral vein, totally 271 cases (80.2%), and the duration of catheterization of this site was 9 (2, 25) d. (3) During the eight years, totally 543 strains of pathogens were isolated, including 353 (65.0%) strains of Gram-negative bacteria, 140 (25.8%) strains of Gram-positive bacteria, and 50 (9.2%) strains of fungi. The top three isolated pathogens with isolation rate from high to low were and accounting for 23.2% (126/543), 17.1% (93/543), and 15.7% (85/543), respectively. Fungi were mainly . Among the the detection rate of MRSA was 98.9% (92/93), and that of MSSA was 1.1% (1/93). (4) Except for the low drug resistance rates to polymyxin B, minocycline, and tigecycline, the drug resistance rates of to the other antibiotics were considerably high (80.1%-100.0%). was not resistant to polymyxin B but highly resistant to netilmicin (88.7%) and piperacillin (92.6%), with resistance rates to the other antibiotics from 34.5% to 62.7%. was not resistant to tigecycline and lowly resistant to imipenem and meropenem (28.9%, 9 imipenem- and meropenem-resistant strains were further confirmed by modified Hodge test), with resistance rates to the other antibiotics from 40.9% to 95.2%. The resistance rates of MRSA to most antibiotics were higher than those of MSSA. MRSA was not resistant to linezolid, vancomycin, teicoplanin, sulfamethoxazole, or tigecycline. The resistance rates of MRSA to clindamycin and erythromycin were 7.9% and 62.0%, respectively, and those to the other antibiotics were higher than 91.5%. Except for the complete resistance to penicillin G and tetracycline, MSSA was not resistant to the other antibiotics. Thirty-three strains of showed resistance to erythromycin-induced clindamycin. Fungi was not resistant to amphotericin B, with drug resistance rates to voriconazole, itraconazole, ketoconazole, and fluconazole from 4.2% to 6.2%. The incidence of CRBSI and mortality of patients with CRBSI are high in BICU of the author's unit, and the main infection site is femoral vein. There are various types of pathogens in patients with CRBSI, and most of them are Gram-negative. The top three isolated pathogens are and accompanying with grim drug resistance phenomenon.
分析烧伤重症监护病房(BICU)导管相关血流感染(CRBSI)患者分离出的病原菌分布及耐药情况。2011年1月至2018年12月,陆军军医大学第一附属医院(第三军医大学)BICU行外周静脉穿刺中心静脉置管的2 264例患者中,159例被诊断为CRBSI,其中男性131例,女性28例,年龄43(1,79)岁。回顾性分析CRBSI患者外周静脉血、中心静脉导管血/中心静脉导管前段标本中主要分离出的病原菌。采用API细菌鉴定试剂盒及全自动微生物鉴定仪鉴定病原菌。采用肉汤微量稀释法或Kirby-Bauer纸片扩散法检测病原菌对氟康唑、伊曲康唑等5种抗真菌药物及替加环素、亚胺培南等37种抗菌药物的耐药性。采用改良Hodge试验进一步鉴定对亚胺培南和美罗培南耐药的菌株。采用D试验检测红霉素诱导的克林霉素耐药情况。应用WHONET 5.6软件分析CRBSI的年发病率、CRBSI患者死亡率、CRBSI病例发生率、感染部位分布、置管时间、革兰阴性菌和革兰阳性菌、真菌、耐甲氧西林金黄色葡萄球菌(MRSA)、甲氧西林敏感金黄色葡萄球菌(MSSA)检测情况以及真菌和主要革兰阴性菌、革兰阳性菌对临床常用抗生素的耐药情况。(1)8年间CRBSI发病率为7.0%(159/2 264),2014年和2017年略高,分别为13.6%(30/221)和11.1%(24/217)。CRBSI患者死亡率为7.5%(12/159)。(2)CRBSI病例发生率为14.9%(338/2 264);主要感染部位为股静脉,共271例(80.2%),该部位置管时间为9(2,25)d。(3)8年间共分离出543株病原菌,其中革兰阴性菌353株(65.0%),革兰阳性菌140株(25.8%),真菌50株(9.2%)。分离率由高到低排名前三位的病原菌分别为大肠埃希菌、肺炎克雷伯菌和鲍曼不动杆菌,分别占23.2%(126/543)、17.1%(93/543)和15.7%(85/543)。真菌主要为白色念珠菌。93株金黄色葡萄球菌中MRSA检出率为98.9%(92/93),MSSA检出率为1.1%(1/93)。(4)大肠埃希菌除对多黏菌素B、米诺环素和替加环素耐药率较低外,对其他抗生素耐药率均较高(80.1% - 100.0%)。肺炎克雷伯菌对多黏菌素B不耐药,但对奈替米星(88.7%)和哌拉西林(92.6%)高度耐药,对其他抗生素耐药率为34.5% - 62.7%。鲍曼不动杆菌对替加环素不耐药,对亚胺培南和美罗培南低度耐药(28.9%,9株亚胺培南和美罗培南耐药菌株经改良Hodge试验进一步确证),对其他抗生素耐药率为40.9% - 95.2%。MRSA对多数抗生素耐药率高于MSSA。MRSA对利奈唑胺、万古霉素、替考拉宁、磺胺甲恶唑或替加环素不耐药。MRSA对克林霉素和红霉素耐药率分别为7.9%和62.0%,对其他抗生素耐药率均高于91.5%。MSSA除对青霉素G和四环素完全耐药外,对其他抗生素均不耐药。33株金黄色葡萄球菌表现为红霉素诱导的克林霉素耐药。真菌对两性霉素B不耐药,对伏立康唑、伊曲康唑、酮康唑和氟康唑耐药率为4.2% - 6.2%。作者单位BICU的CRBSI发病率及CRBSI患者死亡率较高,主要感染部位为股静脉。CRBSI患者病原菌种类多样,以革兰阴性菌为主。分离率排名前三位的病原菌为大肠埃希菌、肺炎克雷伯菌和鲍曼不动杆菌,并伴有严峻的耐药现象。